An interventional study of Dietary supplement for hair loss and Placebo in Occasional Hair Loss, sponsored by Lacer S.A.. Not yet recruiting at 1 site in Spain. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Lacer S.A. (part of Italfarmaco) · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Alopecia with a site in Spain — 8 open to participants now, 11 under way, 3 of them phase 3. Alopecia · Spain.
Among the 29 studies in Alopecia with a site in Spain, this one is the 13th largest by planned enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2026, is one of 11 with no phase, reaches primary completion later than 8 of the 10 other live ones, and was the 27th registered.
512 studies on the registry are indexed under Alopecia; 128 are open to participants now.
Browse Alopecia studies →8 of the 29 studies in Alopecia with a site in Spain are open now. Recruiting first, the newest first:
Pfizer · Sites in Spain, United States, Canada and 8 more countries
Ages 12+
Industrial Farmacéutica Cantabria, S.A. · Sites in Spain
Ages 18–45 · Men only
AI Labs Group S.L · Sites in Spain
Ages 16+
University of Salamanca · Sites in Spain
Ages 18+ · Women only · Healthy volunteers
Eli Lilly and Company · Sites in Spain, United States, Argentina and 9 more countries
Ages 6–17
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 76 Alopecia studies recruiting now, 24 (32%) set no upper age limit and 48 (63%) stop at 75 or younger; 10 take children under 18; 25 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 8
First in 2007; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is above the median of 50 across 431 interventional studies indexed under Alopecia.
Median enrollment 100 across the 21 interventional studies, 30 across the 8 observational. Of the 13 that completed or were terminated, 5 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 29 have an industry lead sponsor. The 10 most frequent:
This study is registered under Lacer S.A., one of the names counted as Italfarmaco. Under that name alone:
Lacer S.A. is the lead sponsor of 13 studies on the registry; 5 are open to participants now.
Italfarmaco has 3 studies filed under Alopecia — fewer than ten, so there is no comparison to draw.
4 of the studies in Alopecia with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07869199Olistic Research Labs S.L.Gut Microbiota and Trichoscopic Changes in Women With Telogen Effluvium on a Multifactorial Drinkable Nutraceutical: A Retrospective Observational Study | 2026-12 |
| NCT07862374Olistic Research Labs S.L.Oral Minoxidil With or Without a Multifactorial Drinkable Nutraceutical in Female Pattern Hair Loss: a Retrospective Study | 2026-12 |
| NCT07111299Olistic Research Labs S.L.Clinical Evaluation of a Nutraceutical Supplement for Hair Growth, Hair Loss and Skin Improvement in Human Volunteers Versus Placebo | 2027-01 |
| NCT07835646Lacer S.A.Evaluation of the Dietary Supplement Effect on Improvement of Hair Condition in Subjects With Occasional Hair Loss. | 2027-02 |
Add all 4 to your calendar (.ics) → With an account.
Among the 29 studies in Alopecia with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to learn if dietary supplement works to help with improving hair condition in subjects with occasional hair loss. It will also learn about its safety. The main question it aims to answer is:
Participants will:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Refusal to provide to participate in the study.
Exposure to intense sunlight or ultraviolet (UV) radiation within the month prior to study enrollment, or anticipated exposure during the study period.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dietary Supplement: Dietary supplement for hair loss
Other: Placebo
Dietary supplement will be taken daily for 2 months
Placebo will be taken daily for 2 months
Change from Baseline in the number of shed hairs at 3 Months
Hair loss will be evaluated by wash and combing test
Time frame: From enrollment to the end of treatment at 3 months
Plan to share: No — Only data included in the publication will be shared.
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Feb 2027, 3 months later.
Of 61 industry-sponsored interventional studies with no phase under Alopecia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's planned 3 months is below that.
Counting every sponsor, half of 146 studies reached it within 12 months; a quarter within 6 and three quarters within 27.
Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Nov 2026, on Nov 18, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.